BR112017007194A2 - compostos de hidroxil purina e aplicações dos mesmos - Google Patents

compostos de hidroxil purina e aplicações dos mesmos

Info

Publication number
BR112017007194A2
BR112017007194A2 BR112017007194A BR112017007194A BR112017007194A2 BR 112017007194 A2 BR112017007194 A2 BR 112017007194A2 BR 112017007194 A BR112017007194 A BR 112017007194A BR 112017007194 A BR112017007194 A BR 112017007194A BR 112017007194 A2 BR112017007194 A2 BR 112017007194A2
Authority
BR
Brazil
Prior art keywords
purine
applications
hydroxyl compounds
hydroxyl
pde2
Prior art date
Application number
BR112017007194A
Other languages
English (en)
Other versions
BR112017007194B1 (pt
Inventor
Long Chaofeng
Li Jian
Zhang Li
Wu Lingyun
Zhang Peng
Chen Shuhui
Chen Xiaoxin
Liu Zhuowei
Original Assignee
Guangdong Zhongsheng Pharmaceutical Co Ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410529928.9A external-priority patent/CN105566324B/zh
Application filed by Guangdong Zhongsheng Pharmaceutical Co Ltd, Medshine Discovery Inc filed Critical Guangdong Zhongsheng Pharmaceutical Co Ltd
Publication of BR112017007194A2 publication Critical patent/BR112017007194A2/pt
Publication of BR112017007194B1 publication Critical patent/BR112017007194B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/14—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with two methyl radicals in positions 1 and 3 and two methyl radicals in positions 7, 8, or 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

compostos de hidroxil purina representados pela fórmula (i), tautômeros ou sais farmaceuticamente aceitáveis dos mesmos, e aplicações dos mesmos como inibidores de pde2 ou tnf-a.
BR112017007194-0A 2014-10-09 2015-09-22 Compostos de hidroxil purina e uso dos mesmos BR112017007194B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410529928.9A CN105566324B (zh) 2014-10-09 2014-10-09 羟基嘌呤类化合物及其应用
CN201410529928.9 2014-10-09
CN201510590904 2015-09-16
CN201510590904.9 2015-09-16
PCT/CN2015/090294 WO2016054971A1 (zh) 2014-10-09 2015-09-22 羟基嘌呤类化合物及其应用

Publications (2)

Publication Number Publication Date
BR112017007194A2 true BR112017007194A2 (pt) 2017-12-26
BR112017007194B1 BR112017007194B1 (pt) 2023-11-07

Family

ID=55652577

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007194-0A BR112017007194B1 (pt) 2014-10-09 2015-09-22 Compostos de hidroxil purina e uso dos mesmos

Country Status (15)

Country Link
US (2) US10098885B2 (pt)
EP (1) EP3205652B1 (pt)
JP (1) JP6527948B2 (pt)
KR (1) KR101997592B1 (pt)
CN (1) CN107001371B (pt)
AU (1) AU2015330490B2 (pt)
BR (1) BR112017007194B1 (pt)
CA (1) CA2964018C (pt)
IL (1) IL251659B (pt)
MX (1) MX2017004655A (pt)
NZ (1) NZ731344A (pt)
RU (1) RU2673458C1 (pt)
SG (1) SG11201702900SA (pt)
TW (1) TWI689511B (pt)
WO (1) WO2016054971A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330490B2 (en) 2014-10-09 2018-08-09 Guangdong Raynovent Biotech Co., Ltd. Hydroxyl purine compounds and applications thereof
WO2016184313A1 (zh) 2015-05-20 2016-11-24 南京明德新药研发股份有限公司 羟基嘌呤类化合物及其应用
EP3299371B1 (en) * 2015-05-20 2021-08-25 Guangdong Raynovent Biotech Co., Ltd. Hydroxyl purine compounds and use thereof
US10399981B2 (en) 2015-10-29 2019-09-03 Guangdong Raynovent Biotech Co., Ltd. Crystal form A of 7-(cyclopropylmethyl)-1-(((cis )-4-hydroxy-4-methylcyclohexyl)methyl)-3-methyl-1H-purine-2,6-(3H,7H)-dione for treating liver diseases
RU2738646C2 (ru) 2016-04-01 2020-12-15 РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС Модуляторы эстрогеновых рецепторов
JP2019014656A (ja) * 2017-07-03 2019-01-31 宇部興産株式会社 プリン誘導体化合物及びプリン誘導体化合物変性共役ジエン重合体
JP2022543832A (ja) 2019-08-06 2022-10-14 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 変異体を治療するためのエストロゲン受容体調節剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5426349B2 (pt) 1973-10-26 1979-09-03
JPS601542B2 (ja) * 1977-05-18 1985-01-16 ダイキン工業株式会社 吸収式蓄熱冷暖房装置
JPS55118488A (en) 1979-03-05 1980-09-11 Eisai Co Ltd Theobromine derivative and its preparation
DE3421072A1 (de) 1984-06-06 1985-12-12 Heinrich Mack Nachf., 7918 Illertissen 1,4:3,6-dianhydro-hexit-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US5321029A (en) 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
NZ240644A (en) 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
DK0584347T3 (da) 1992-03-04 2003-02-24 Cell Therapeutics Inc Enantiomere hydroxylerede xanthinforbindelser
US5580874A (en) 1992-03-04 1996-12-03 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
US5804584A (en) 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
WO1995022546A1 (en) * 1994-02-18 1995-08-24 Cell Therapeutics, Inc. Intracellular signalling mediators
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5775205A (en) * 1996-12-16 1998-07-07 Melton; Bruce W. Infuser unit for beverages
EP0956855B1 (en) 1998-04-24 2003-03-12 K.U. Leuven Research & Development Immunosuppressive effects of 8 substituted xanthine derivatives
AU5038499A (en) * 1998-07-31 2000-02-28 Aventis Pharma Deutschland Gmbh Use of xanthine derivatives for treating erectile disorder
TWI347845B (en) * 2002-03-06 2011-09-01 Nycomed Gmbh Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
US20070004745A1 (en) 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
EP1893614B1 (en) 2005-06-21 2013-05-22 The University Court of the University of Dundee Inhibitor compounds
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US20140296263A1 (en) * 2011-07-19 2014-10-02 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2753333B1 (en) 2011-10-27 2017-06-21 ProtaMed, Inc. Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies
CN102603737B (zh) 2012-02-17 2014-04-09 四川大学 吡啶并嘧啶酮类衍生物以及在制备抗肿瘤药物方面的用途
CN111233863B (zh) 2014-10-09 2022-10-25 广东众生睿创生物科技有限公司 羟基嘌呤类化合物及其应用
AU2015330490B2 (en) 2014-10-09 2018-08-09 Guangdong Raynovent Biotech Co., Ltd. Hydroxyl purine compounds and applications thereof
US10399981B2 (en) * 2015-10-29 2019-09-03 Guangdong Raynovent Biotech Co., Ltd. Crystal form A of 7-(cyclopropylmethyl)-1-(((cis )-4-hydroxy-4-methylcyclohexyl)methyl)-3-methyl-1H-purine-2,6-(3H,7H)-dione for treating liver diseases

Also Published As

Publication number Publication date
MX2017004655A (es) 2018-03-27
CA2964018A1 (en) 2016-04-14
CN107001371B (zh) 2019-07-05
USRE49128E1 (en) 2022-07-12
EP3205652A1 (en) 2017-08-16
BR112017007194B1 (pt) 2023-11-07
IL251659A0 (en) 2017-06-29
KR20170066588A (ko) 2017-06-14
US20170326149A1 (en) 2017-11-16
KR101997592B1 (ko) 2019-07-08
AU2015330490B2 (en) 2018-08-09
AU2015330490A1 (en) 2017-05-18
RU2673458C1 (ru) 2018-11-27
SG11201702900SA (en) 2017-05-30
NZ731344A (en) 2018-08-31
EP3205652B1 (en) 2022-03-09
TW201619160A (zh) 2016-06-01
TWI689511B (zh) 2020-04-01
EP3205652A4 (en) 2017-08-16
CA2964018C (en) 2019-04-02
CN107001371A (zh) 2017-08-01
JP2017531695A (ja) 2017-10-26
IL251659B (en) 2021-04-29
JP6527948B2 (ja) 2019-06-12
US10098885B2 (en) 2018-10-16
WO2016054971A1 (zh) 2016-04-14

Similar Documents

Publication Publication Date Title
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2016002394A1 (es) Derivados de quinolina como inhibidores de smo
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
BR112017007194A2 (pt) compostos de hidroxil purina e aplicações dos mesmos
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
PH12017500207A1 (en) Indoles for use in influenza virus infection
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201690098A1 (ru) Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CL2018000649A1 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx / ca
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
UY34654A (es) Inhibidores de la beta-secretasa
EA201692143A1 (ru) Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
BR112017028549A2 (pt) derivados de pirimidina como inibidores de btk e usos dos mesmos
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
EA201791530A1 (ru) НОВЫЕ N-АЦИЛАРИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ АМИНОАЦИЛ-тРНК СИНТЕТАЗЫ
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
CL2016001488A1 (es) Quinazolin-thf-aminas como inhibidores de pde1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: MEDSHINE DISCOVERY INC. (CN) ; GUANGDONG RAYNOVENT BIOTECH CO., LTD. (CN)

B25A Requested transfer of rights approved

Owner name: GUANGDONG RAYNOVENT BIOTECH CO., LTD. (CN)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: GUANGDONG RAYNOVENT BIOTECH CO., LTD. (CN)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/09/2015, OBSERVADAS AS CONDICOES LEGAIS